Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Baricitinib symbols : INCY save search
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.2%
H: 3.93%
C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Published: 2021-08-03 (Crawled : 10:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.75%
H: 5.97%
C: 4.59%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.7%
H: 0.31%
C: 0.04%
covid baricitinib covid-19
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
Published: 2021-07-29 (Crawled : 17:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.64%
H: 0.14%
C: -1.41%
covid baricitinib fda oxygen merge
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-07-16 (Crawled : 14:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
new drug baricitinib treatment dermatitis drug atopic dermatitis
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Published: 2021-04-20 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.28%
H: 2.1%
C: 2.01%
growth phase 3 hair regrowth baricitinib
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Published: 2021-04-08 (Crawled : 11:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.35%
H: 0.56%
C: -0.19%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.76%
H: 0.74%
C: -1.43%
covid results phase 3 baricitinib
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-04-06 (Crawled : 23:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.11%
H: 0.51%
C: -1.02%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.3%
H: 1.07%
C: 0.22%
new drug treatment dermatitis drug baricitinib atopic dermatitis
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
Published: 2021-03-03 (Crawled : 12:09) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.38%
H: 0.46%
C: -0.67%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.3%
H: 0.33%
C: -2.94%
growth phase 3 trial baricitinib hair regrowth
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
Published: 2020-12-11 (Crawled : 19:11) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
| Email alert
Add to watchlist
covid trial baricitinib
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.